LCM
ATOS icon

LVM Capital Management’s Atossa Therapeutics ATOS Stock Holding History

LVM Capital Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,400
Closed -$12K – 160
2025
Q4 		$12K Hold
1,400
– – ﹤0.01% 156
2025
Q3 		$18K Hold
1,400
– – ﹤0.01% 159
2025
Q2 		$17K Hold
1,400
– – ﹤0.01% 148
2025
Q1 		$14K Hold
1,400
– – ﹤0.01% 146
2024
Q4 		$20K Hold
1,400
– – ﹤0.01% 150
2024
Q3 		$25K Hold
1,400
– – ﹤0.01% 137
2024
Q2 		$25K Hold
1,400
– – ﹤0.01% 137
2024
Q1 		$38K Hold
1,400
– – ﹤0.01% 135
2023
Q4 		$18K Hold
1,400
– – ﹤0.01% 140
2023
Q3 		$15K Hold
1,400
– – ﹤0.01% 133
2023
Q2 		$26K Buy
+1,400
New +$17K ﹤0.01% 135

Other funds holding ATOS

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LVM Capital Management's ATOS Position: Q1 2026 in Review

LVM Capital Management sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 1,400 shares — an estimated $12K sold.

LVM Capital Management first reported a position in ATOS in Q2 2023 and held it in 11 quarters. The position peaked at $38K in Q1 2024. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • LVM Capital Management reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • LVM Capital Management sold 1,400 Atossa Therapeutics shares in Q1 2026, an estimated $12K.
  • LVM Capital Management first reported a position in Atossa Therapeutics in Q2 2023 and held it in 11 quarters.
  • LVM Capital Management's Atossa Therapeutics position peaked at $38K in Q1 2024.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on LVM Capital Management's 13F filing for Q1 2026, filed 2 Apr 2026.